NEW YORK ( TheStreet) - The 10 large-cap stocks rated A-minus or higher by TheStreet Ratings with the highest dividend yields are all trading close to consensus price targets, but that's no surprise with such solid financials and rich dividend yields. Starting with companies with market capitalizations exceeding $5 billion rated A-minus (strong buy) or higher by TheStreet Ratings, we pared down the group to the 10 stocks with the highest forward dividend yields, based on the most recent quarterly payout. Not surprisingly, electric utilities and energy service companies dominate the list. Total returns assume reinvested dividends. 10. Bristol-Myers SquibbCompany Profile Bristol-Meyers Squibb is a global pharmaceutical company headquartered in New York. Shares closed at $27.68 Thursday with one-year total return - assuming dividends are reinvested - of 31%. Based on a quarterly payout of 32 cents, the shares have a forward dividend yield of 4.62%. Income Statement The company reported second-quarter net earnings to common stockholders of $927 million, or 53 cents a share, up from $743 million, or 43 cents a share, the previous quarter but down from $983 million, or 49 cents a share, a year earlier, when results included $103 million or 5 cents a share from discontinued operations. Net sales for the second quarter were $4.8 billion, up 2% from a year earlier. During the second quarter, the company also began a $3 billion share repurchase program. Balance Sheet The company has strong liquidity with a quick ratio of 1.80, showing a clear ability to cover short term cash needs. The ratio of debt to capital is 0.29. Stock Ratios Shares trade for 11.4 times earnings, which is higher than the P/E for other major pharmaceuticals including Eli Lilly ( LLY) which trades at 8.5 times earnings and Sanofi-Aventis SA ( SNY) which is trading at 9.6 times earnings. Large-cap sector players trading at higher multiples include Abbot Laboratories ( ABT)which trades for 14.9 times earnings and Teva Pharmaceutical ( TEVA), which trades for 18.3 times earnings. Analyst Ratings Out of 25 analysts covering Bristol-Meyers Squibb, 11 rate the shares a buy, while 11 recommend investors hold and three recommend selling the shares.